A French expert consensus outlined practical guidance for relapsing multiple sclerosis patients continuing beyond year four on cladribine tablets. The panel addressed the treatment-decision gap once randomized-trial evidence is no longer directly applicable, focusing on pragmatic clinical pathways. Published in the Journal of Neurology, the recommendations aim to support decision-making in routine care where long-term guidance can be sparse. The issue is particularly relevant for MS specialists managing sustained disease control while balancing treatment timing and patient-specific risk. For biotech stakeholders, consensus-driven guidance can influence real-world utilization patterns and reinforce the need for longer follow-up evidence in disease-modifying therapies.